FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039404912> ?p ?o ?g. }

• W2039404912 endingPage "515" @default.
• W2039404912 startingPage "507" @default.
• W2039404912 abstract "Article AbstractObjective: The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome.Method: Patients who completed a 6-week, double-blind, placebo-controlled study evaluating the efficacy of fixed doses of once-daily lurasidone (40 or 120 mg) or olanzapine 15 mg (to confirm assay sensitivity) were eligible to receive flexibly dosed lurasidone 40 to 120 mg/d in this 6-month, open-label extension study (conducted from March 2008 to December 2009). Assessments of safety and tolerability were conducted at open-label baseline, at day 10, and monthly thereafter.Results: Of 254 enrolled patients, 113 (44.5%) completed 6 months of open-label treatment. During the open-label study (month 6 observed cases), small decreases were observed in mean weight (−0.1 kg) and median lipid levels (total cholesterol, −6.5 mg/dL; low-density lipoprotein, 0.0 mg/dL; high-density lipoprotein, 0.0 mg/dL; triglycerides, −8.5 mg/dL). Patients previously treated with olanzapine (n = 69) experienced decrease in weight and improvement in lipid levels, whereas patients previously treated with lurasidone (n = 115) or placebo (n = 62) experienced minimal changes. No clinically meaningful changes were observed in median prolactin levels. The 2 most commonly reported adverse events were akathisia (13.0%) and insomnia (11.0%). Persistent antipsychotic efficacy of lurasidone was shown for patients who had previously received lurasidone, olanzapine, or placebo; further reductions from open-label baseline to final visit were observed in mean PANSS total score (−8.7) for all patients.Conclusions: Open-label treatment with flexibly dosed lurasidone (40-120 mg/d) was generally safe, well tolerated, and effective over a 6-month period in patients who had completed a preceding 6-week, double-blind study.Trial Registration: ClinicalTrials.gov identifier: NCT00615433J Clin Psychiatry © Copyright 2013 Physicians Postgraduate Press, Inc.Submitted: August 7, 2012; accepted February 15, 2013. Online ahead of print: March 13, 2013 (doi:10.4088/JCP.12m08084).Corresponding author: Stephen M. Stahl, MD, PhD, 1930 Palomar Point Way, Ste 103, Carlsbad, CA 92008 (smstahl@neiglobal.com)." @default.
• W2039404912 created "2016-06-24" @default.
• W2039404912 creator A5014310189 @default.
• W2039404912 creator A5015501263 @default.
• W2039404912 creator A5028328307 @default.
• W2039404912 creator A5049908334 @default.
• W2039404912 creator A5059896455 @default.
• W2039404912 creator A5066553937 @default.
• W2039404912 date "2013-03-13" @default.
• W2039404912 modified "2023-10-03" @default.
• W2039404912 title "Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo" @default.
• W2039404912 cites W1604217211 @default.
• W2039404912 cites W180335173 @default.
• W2039404912 cites W1839220452 @default.
• W2039404912 cites W1968223004 @default.
• W2039404912 cites W1972203123 @default.
• W2039404912 cites W1979797229 @default.
• W2039404912 cites W1981740077 @default.
• W2039404912 cites W1991475958 @default.
• W2039404912 cites W1993446055 @default.
• W2039404912 cites W1994877202 @default.
• W2039404912 cites W1997910708 @default.
• W2039404912 cites W1999689270 @default.
• W2039404912 cites W2002278536 @default.
• W2039404912 cites W2002701207 @default.
• W2039404912 cites W2014202818 @default.
• W2039404912 cites W2027300442 @default.
• W2039404912 cites W2027838310 @default.
• W2039404912 cites W2045697057 @default.
• W2039404912 cites W2051386775 @default.
• W2039404912 cites W2067763161 @default.
• W2039404912 cites W2072587904 @default.
• W2039404912 cites W2078053761 @default.
• W2039404912 cites W2086479492 @default.
• W2039404912 cites W2090658963 @default.
• W2039404912 cites W2096202887 @default.
• W2039404912 cites W2097129122 @default.
• W2039404912 cites W2100557888 @default.
• W2039404912 cites W2137044087 @default.
• W2039404912 cites W2165379748 @default.
• W2039404912 cites W2415493263 @default.
• W2039404912 cites W2760351771 @default.
• W2039404912 cites W3035656926 @default.
• W2039404912 cites W3090293687 @default.
• W2039404912 doi "https://doi.org/10.4088/jcp.12m08084" @default.
• W2039404912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23541189" @default.
• W2039404912 hasPublicationYear "2013" @default.
• W2039404912 type Work @default.
• W2039404912 sameAs 2039404912 @default.
• W2039404912 citedByCount "58" @default.
• W2039404912 countsByYear W20394049122013 @default.
• W2039404912 countsByYear W20394049122014 @default.
• W2039404912 countsByYear W20394049122015 @default.
• W2039404912 countsByYear W20394049122016 @default.
• W2039404912 countsByYear W20394049122017 @default.
• W2039404912 countsByYear W20394049122018 @default.
• W2039404912 countsByYear W20394049122019 @default.
• W2039404912 countsByYear W20394049122020 @default.
• W2039404912 countsByYear W20394049122021 @default.
• W2039404912 countsByYear W20394049122022 @default.
• W2039404912 countsByYear W20394049122023 @default.
• W2039404912 crossrefType "journal-article" @default.
• W2039404912 hasAuthorship W2039404912A5014310189 @default.
• W2039404912 hasAuthorship W2039404912A5015501263 @default.
• W2039404912 hasAuthorship W2039404912A5028328307 @default.
• W2039404912 hasAuthorship W2039404912A5049908334 @default.
• W2039404912 hasAuthorship W2039404912A5059896455 @default.
• W2039404912 hasAuthorship W2039404912A5066553937 @default.
• W2039404912 hasBestOaLocation W20394049121 @default.
• W2039404912 hasConcept C118552586 @default.
• W2039404912 hasConcept C126322002 @default.
• W2039404912 hasConcept C142724271 @default.
• W2039404912 hasConcept C197934379 @default.
• W2039404912 hasConcept C204787440 @default.
• W2039404912 hasConcept C27081682 @default.
• W2039404912 hasConcept C2776412080 @default.
• W2039404912 hasConcept C2776619155 @default.
• W2039404912 hasConcept C2776701107 @default.
• W2039404912 hasConcept C2776921671 @default.
• W2039404912 hasConcept C2777393122 @default.
• W2039404912 hasConcept C2778375690 @default.
• W2039404912 hasConcept C2780211496 @default.
• W2039404912 hasConcept C2780494398 @default.
• W2039404912 hasConcept C71924100 @default.
• W2039404912 hasConcept C90924648 @default.
• W2039404912 hasConcept C98274493 @default.
• W2039404912 hasConceptScore W2039404912C118552586 @default.
• W2039404912 hasConceptScore W2039404912C126322002 @default.
• W2039404912 hasConceptScore W2039404912C142724271 @default.
• W2039404912 hasConceptScore W2039404912C197934379 @default.
• W2039404912 hasConceptScore W2039404912C204787440 @default.
• W2039404912 hasConceptScore W2039404912C27081682 @default.
• W2039404912 hasConceptScore W2039404912C2776412080 @default.
• W2039404912 hasConceptScore W2039404912C2776619155 @default.
• W2039404912 hasConceptScore W2039404912C2776701107 @default.
• W2039404912 hasConceptScore W2039404912C2776921671 @default.
• W2039404912 hasConceptScore W2039404912C2777393122 @default.
• W2039404912 hasConceptScore W2039404912C2778375690 @default.

• next